img

Global and India Anti-VEGT Drugs Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and India Anti-VEGT Drugs Market Report & Forecast 2024-2034

Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
The global Anti-VEGT Drugs revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
In India, the Anti-VEGT Drugs revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Anti-VEGT Drugs include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Anti-VEGT Drugs market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Anti-VEGT Drugs will continue to grow rapidly in the future.
Global Anti-VEGT Drugs Scope and Market Size
Anti-VEGT Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Anti-VEGT Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Anti-VEGT Drugs market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.



By Company


Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others

Segment by Application


Oncology
Ophthalmology
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Anti-VEGT Drugs definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Anti-VEGT Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Anti-VEGT Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGT Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Anti-VEGT Drugs Product Introduction
1.2 Global Anti-VEGT Drugs Outlook 2018 VS 2022 VS 2029
1.2.1 Global Anti-VEGT Drugs Sales in US$ Million for the Year 2018-2029
1.2.2 Global Anti-VEGT Drugs Sales in Volume for the Year 2018-2029
1.3 India Anti-VEGT Drugs Outlook 2018 VS 2022 VS 2029
1.3.1 India Anti-VEGT Drugs Sales in US$ Million for the Year 2018-2029
1.3.2 India Anti-VEGT Drugs Sales in Volume for the Year 2018-2029
1.4 Anti-VEGT Drugs Market Size, India VS Global, 2018 VS 2022 VS 2029
1.4.1 The Market Share of India Anti-VEGT Drugs in Global, 2018 VS 2022 VS 2029
1.4.2 The Growth Rate of Anti-VEGT Drugs Market Size, India VS Global, 2018 VS 2022 VS 2029
1.5 Anti-VEGT Drugs Market Dynamics
1.5.1 Anti-VEGT Drugs Industry Trends
1.5.2 Anti-VEGT Drugs Market Drivers
1.5.3 Anti-VEGT Drugs Market Challenges
1.5.4 Anti-VEGT Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Anti-VEGT Drugs by Type
2.1 Anti-VEGT Drugs Market Segment by Type
2.1.1 Tyrosine Kinase Inhibitors
2.1.2 Monoclonal Antibodies
2.1.3 Others
2.2 Global Anti-VEGT Drugs Market Size by Type
2.2.1 Global Anti-VEGT Drugs Sales in Value, by Type (2018, 2022 & 2029)
2.2.2 Global Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
2.2.3 Global Anti-VEGT Drugs Average Selling Price (ASP) by Type (2018, 2022 & 2029)
2.3 India Anti-VEGT Drugs Market Size by Type
2.3.1 India Anti-VEGT Drugs Sales in Value, by Type (2018, 2022 & 2029)
2.3.2 India Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
2.3.3 India Anti-VEGT Drugs Average Selling Price (ASP) by Type (2018, 2022 & 2029)
3 Anti-VEGT Drugs by Application
3.1 Anti-VEGT Drugs Market Segment by Application
3.1.1 Oncology
3.1.2 Ophthalmology
3.1.3 Others
3.2 Global Anti-VEGT Drugs Market Size by Application
3.2.1 Global Anti-VEGT Drugs Sales in Value, by Application (2018, 2022 & 2029)
3.2.2 Global Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
3.3.3 Global Anti-VEGT Drugs Average Selling Price (ASP) by Application (2018, 2022 & 2029)
3.3 India Anti-VEGT Drugs Market Size by Application
3.3.1 India Anti-VEGT Drugs Sales in Value, by Application (2018, 2022 & 2029)
3.3.2 India Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
3.3.3 India Anti-VEGT Drugs Average Selling Price (ASP) by Application (2018, 2022 & 2029)
4 Global Anti-VEGT Drugs Competitor Landscape by Company
4.1 Global Anti-VEGT Drugs Market Size by Company
4.1.1 Global Key Manufacturers of Anti-VEGT Drugs, Ranked by Revenue (2022)
4.1.2 Global Anti-VEGT Drugs Revenue by Manufacturer (2018-2024)
4.1.3 Global Anti-VEGT Drugs Sales by Manufacturer (2018-2024)
4.1.4 Global Anti-VEGT Drugs Price by Manufacturer (2018-2024)
4.2 Global Anti-VEGT Drugs Concentration Ratio (CR)
4.2.1 Anti-VEGT Drugs Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Anti-VEGT Drugs in 2022
4.2.3 Global Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Anti-VEGT Drugs, Product Offered and Application
4.5 Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India Anti-VEGT Drugs Market Size by Company
4.7.1 Key Players of Anti-VEGT Drugs in India, Ranked by Revenue (2022)
4.7.2 India Anti-VEGT Drugs Revenue by Players (2018-2024)
4.7.3 India Anti-VEGT Drugs Sales by Players (2018-2024)
5 Global Anti-VEGT Drugs Market Size by Region
5.1 Global Anti-VEGT Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Anti-VEGT Drugs Market Size in Volume by Region (2018-2029)
5.2.1 Global Anti-VEGT Drugs Sales in Volume by Region: 2018-2024
5.2.2 Global Anti-VEGT Drugs Sales in Volume Forecast by Region (2024-2029)
5.3 Global Anti-VEGT Drugs Market Size in Value by Region (2018-2029)
5.3.1 Global Anti-VEGT Drugs Sales in Value by Region: 2018-2024
5.3.2 Global Anti-VEGT Drugs Sales in Value by Region: 2024-2029
6 Americas
6.1 Americas Anti-VEGT Drugs Market Size YoY Growth 2018-2029
6.2 Americas Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
6.3 Americas Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
6.4 Americas Anti-VEGT Drugs Market Facts & Figures by Country (2018, 2022 & 2029)
6.4.1 Americas Anti-VEGT Drugs Sales in Value by Country (2018, 2022 & 2029)
6.4.2 Americas Anti-VEGT Drugs Sales in Volume by Country (2018, 2022 & 2029)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Anti-VEGT Drugs Market Size YoY Growth 2018-2029
7.2 EMEA Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
7.3 EMEA Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
7.4 EMEA Anti-VEGT Drugs Market Facts & Figures by Country (2018, 2022 & 2029)
7.4.1 EMEA Anti-VEGT Drugs Sales in Value by Country (2018, 2022 & 2029)
7.4.2 EMEA Anti-VEGT Drugs Sales in Volume by Country (2018, 2022 & 2029)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Anti-VEGT Drugs Market Size YoY Growth 2018-2029
8.2 China Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
8.3 China Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
9 APAC
9.1 APAC Anti-VEGT Drugs Market Size YoY Growth 2018-2029
9.2 APAC Anti-VEGT Drugs Sales in Volume, by Type (2018, 2022 & 2029)
9.3 APAC Anti-VEGT Drugs Sales in Volume, by Application (2018, 2022 & 2029)
9.4 APAC Anti-VEGT Drugs Market Facts & Figures by Region (2018, 2022 & 2029)
9.4.1 APAC Anti-VEGT Drugs Sales in Value by Region (2018, 2022 & 2029)
9.4.2 APAC Anti-VEGT Drugs Sales in Volume by Region (2018, 2022 & 2029)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Genentech (Roche)
10.1.1 Genentech (Roche) Company Information
10.1.2 Genentech (Roche) Description and Business Overview
10.1.3 Genentech (Roche) Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Genentech (Roche) Anti-VEGT Drugs Products Offered
10.1.5 Genentech (Roche) Recent Development
10.2 Regeneron Pharmaceuticals
10.2.1 Regeneron Pharmaceuticals Company Information
10.2.2 Regeneron Pharmaceuticals Description and Business Overview
10.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Products Offered
10.2.5 Regeneron Pharmaceuticals Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Description and Business Overview
10.3.3 Novartis Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Novartis Anti-VEGT Drugs Products Offered
10.3.5 Novartis Recent Development
10.4 AstraZeneca
10.4.1 AstraZeneca Company Information
10.4.2 AstraZeneca Description and Business Overview
10.4.3 AstraZeneca Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 AstraZeneca Anti-VEGT Drugs Products Offered
10.4.5 AstraZeneca Recent Development
10.5 Bayer
10.5.1 Bayer Company Information
10.5.2 Bayer Description and Business Overview
10.5.3 Bayer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Bayer Anti-VEGT Drugs Products Offered
10.5.5 Bayer Recent Development
10.6 Abbott
10.6.1 Abbott Company Information
10.6.2 Abbott Description and Business Overview
10.6.3 Abbott Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Abbott Anti-VEGT Drugs Products Offered
10.6.5 Abbott Recent Development
10.7 Santen
10.7.1 Santen Company Information
10.7.2 Santen Description and Business Overview
10.7.3 Santen Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Santen Anti-VEGT Drugs Products Offered
10.7.5 Santen Recent Development
10.8 Pfizer
10.8.1 Pfizer Company Information
10.8.2 Pfizer Description and Business Overview
10.8.3 Pfizer Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Pfizer Anti-VEGT Drugs Products Offered
10.8.5 Pfizer Recent Development
10.9 Sanofi
10.9.1 Sanofi Company Information
10.9.2 Sanofi Description and Business Overview
10.9.3 Sanofi Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Sanofi Anti-VEGT Drugs Products Offered
10.9.5 Sanofi Recent Development
10.10 Bristol-Myers Squibb
10.10.1 Bristol-Myers Squibb Company Information
10.10.2 Bristol-Myers Squibb Description and Business Overview
10.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Products Offered
10.10.5 Bristol-Myers Squibb Recent Development
10.11 GlaxoSmithKline
10.11.1 GlaxoSmithKline Company Information
10.11.2 GlaxoSmithKline Description and Business Overview
10.11.3 GlaxoSmithKline Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 GlaxoSmithKline Anti-VEGT Drugs Products Offered
10.11.5 GlaxoSmithKline Recent Development
10.12 Eli Lilly & Company
10.12.1 Eli Lilly & Company Company Information
10.12.2 Eli Lilly & Company Description and Business Overview
10.12.3 Eli Lilly & Company Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Eli Lilly & Company Anti-VEGT Drugs Products Offered
10.12.5 Eli Lilly & Company Recent Development
10.13 Chugai Pharma
10.13.1 Chugai Pharma Company Information
10.13.2 Chugai Pharma Description and Business Overview
10.13.3 Chugai Pharma Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Chugai Pharma Anti-VEGT Drugs Products Offered
10.13.5 Chugai Pharma Recent Development
10.14 Kanghong Pharmaceutical
10.14.1 Kanghong Pharmaceutical Company Information
10.14.2 Kanghong Pharmaceutical Description and Business Overview
10.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Products Offered
10.14.5 Kanghong Pharmaceutical Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Anti-VEGT Drugs Industry Chain Analysis
11.2 Anti-VEGT Drugs Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Anti-VEGT Drugs Production Mode & Process
11.4 Anti-VEGT Drugs Sales and Marketing
11.4.1 Anti-VEGT Drugs Sales Channels
11.4.2 Anti-VEGT Drugs Distributors
11.5 Anti-VEGT Drugs Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Anti-VEGT Drugs CAGR in Value, India VS Global, 2018 VS 2022 VS 2029
Table 2. Anti-VEGT Drugs Market Trends
Table 3. Anti-VEGT Drugs Market Drivers
Table 4. Anti-VEGT Drugs Market Challenges
Table 5. Anti-VEGT Drugs Market Restraints
Table 6. Global Anti-VEGT Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. India Anti-VEGT Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Anti-VEGT Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 9. India Anti-VEGT Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 10. Global Key Manufacturers of Anti-VEGT Drugs, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Anti-VEGT Drugs Revenue by Manufacturer, (US$ Million), 2018-2024
Table 12. Global Anti-VEGT Drugs Revenue Share by Manufacturer, 2018-2024
Table 13. Global Anti-VEGT Drugs Sales by Manufacturer, (K Units), 2018-2024
Table 14. Global Anti-VEGT Drugs Sales Share by Manufacturer, 2018-2024
Table 15. Global Anti-VEGT Drugs Price by Manufacturer (2018-2024) & (US$/Unit)
Table 16. Global Anti-VEGT Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Anti-VEGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGT Drugs as of 2022)
Table 18. Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Anti-VEGT Drugs, Product Offered and Application
Table 20. Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Anti-VEGT Drugs in India, Ranked by Revenue (2022) & (US$ million)
Table 23. India Anti-VEGT Drugs Revenue by Players, (US$ Million), (2018-2024)
Table 24. India Anti-VEGT Drugs Revenue Share by Players, (2018-2024)
Table 25. India Anti-VEGT Drugs Sales by Players, (K Units), (2018-2024)
Table 26. India Anti-VEGT Drugs Sales Share by Players, (2018-2024)
Table 27. Global Anti-VEGT Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 28. Global Anti-VEGT Drugs Sales in Volume by Region (2018-2024) & (K Units)
Table 29. Global Anti-VEGT Drugs Sales in Volume Forecast by Region (2024-2029) & (K Units)
Table 30. Global Anti-VEGT Drugs Sales in Value by Region (2018-2024) & (US$ Million)
Table 31. Global Anti-VEGT Drugs Sales in Value Forecast by Region (2024-2029) & (US$ Million)
Table 32. Americas Anti-VEGT Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. Americas Anti-VEGT Drugs Sales in Value by Country (2018-2024) & (US$ Million)
Table 34. Americas Anti-VEGT Drugs Sales in Value by Country (2024-2029) & (US$ Million)
Table 35. Americas Anti-VEGT Drugs Sales in Volume by Country (2018-2024) & (K Units)
Table 36. Americas Anti-VEGT Drugs Sales in Volume by Country (2024-2029) & (K Units)
Table 37. EMEA Anti-VEGT Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. EMEA Anti-VEGT Drugs Sales in Value by Country (2018-2024) & (US$ Million)
Table 39. EMEA Anti-VEGT Drugs Sales in Value by Country (2024-2029) & (US$ Million)
Table 40. EMEA Anti-VEGT Drugs Sales in Volume by Country (2018-2024) & (K Units)
Table 41. EMEA Anti-VEGT Drugs Sales in Volume by Country (2024-2029) & (K Units)
Table 42. APAC Anti-VEGT Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. APAC Anti-VEGT Drugs Sales in Value by Country (2018-2024) & (US$ Million)
Table 44. APAC Anti-VEGT Drugs Sales in Value by Country (2024-2029) & (US$ Million)
Table 45. APAC Anti-VEGT Drugs Sales in Volume by Country (2018-2024) & (K Units)
Table 46. APAC Anti-VEGT Drugs Sales in Volume by Country (2024-2029) & (K Units)
Table 47. Genentech (Roche) Company Information
Table 48. Genentech (Roche) Description and Business Overview
Table 49. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 50. Genentech (Roche) Anti-VEGT Drugs Product
Table 51. Genentech (Roche) Recent Development
Table 52. Regeneron Pharmaceuticals Company Information
Table 53. Regeneron Pharmaceuticals Description and Business Overview
Table 54. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 55. Regeneron Pharmaceuticals Anti-VEGT Drugs Product
Table 56. Regeneron Pharmaceuticals Recent Development
Table 57. Novartis Company Information
Table 58. Novartis Description and Business Overview
Table 59. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 60. Novartis Anti-VEGT Drugs Product
Table 61. Novartis Recent Development
Table 62. AstraZeneca Company Information
Table 63. AstraZeneca Description and Business Overview
Table 64. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 65. AstraZeneca Anti-VEGT Drugs Product
Table 66. AstraZeneca Recent Development
Table 67. Bayer Company Information
Table 68. Bayer Description and Business Overview
Table 69. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 70. Bayer Anti-VEGT Drugs Product
Table 71. Bayer Recent Development
Table 72. Abbott Company Information
Table 73. Abbott Description and Business Overview
Table 74. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 75. Abbott Anti-VEGT Drugs Product
Table 76. Abbott Recent Development
Table 77. Santen Company Information
Table 78. Santen Description and Business Overview
Table 79. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 80. Santen Anti-VEGT Drugs Product
Table 81. Santen Recent Development
Table 82. Pfizer Company Information
Table 83. Pfizer Description and Business Overview
Table 84. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 85. Pfizer Anti-VEGT Drugs Product
Table 86. Pfizer Recent Development
Table 87. Sanofi Company Information
Table 88. Sanofi Description and Business Overview
Table 89. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 90. Sanofi Anti-VEGT Drugs Product
Table 91. Sanofi Recent Development
Table 92. Bristol-Myers Squibb Company Information
Table 93. Bristol-Myers Squibb Description and Business Overview
Table 94. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 95. Bristol-Myers Squibb Anti-VEGT Drugs Product
Table 96. Bristol-Myers Squibb Recent Development
Table 97. GlaxoSmithKline Company Information
Table 98. GlaxoSmithKline Description and Business Overview
Table 99. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 100. GlaxoSmithKline Anti-VEGT Drugs Product
Table 101. GlaxoSmithKline Recent Development
Table 102. Eli Lilly & Company Company Information
Table 103. Eli Lilly & Company Description and Business Overview
Table 104. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 105. Eli Lilly & Company Anti-VEGT Drugs Product
Table 106. Eli Lilly & Company Recent Development
Table 107. Chugai Pharma Company Information
Table 108. Chugai Pharma Description and Business Overview
Table 109. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Chugai Pharma Anti-VEGT Drugs Product
Table 111. Chugai Pharma Recent Development
Table 112. Kanghong Pharmaceutical Company Information
Table 113. Kanghong Pharmaceutical Description and Business Overview
Table 114. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Kanghong Pharmaceutical Anti-VEGT Drugs Product
Table 116. Kanghong Pharmaceutical Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Anti-VEGT Drugs Customers List
Table 120. Anti-VEGT Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGT Drugs Product Picture
Figure 2. Global Anti-VEGT Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Anti-VEGT Drugs Market Size 2018-2029 (US$ Million)
Figure 4. Global Anti-VEGT Drugs Sales 2018-2029 (K Units)
Figure 5. India Anti-VEGT Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 6. India Anti-VEGT Drugs Market Size 2018-2029 (US$ Million)
Figure 7. India Anti-VEGT Drugs Sales 2018-2029 (K Units)
Figure 8. India Anti-VEGT Drugs Market Share in Global, in Value (US$ Million) 2018-2029
Figure 9. India Anti-VEGT Drugs Market Share in Global, in Volume (K Units) 2018-2029
Figure 10. Anti-VEGT Drugs Report Years Considered
Figure 11. Product Picture of Tyrosine Kinase Inhibitors
Figure 12. Product Picture of Monoclonal Antibodies
Figure 13. Product Picture of Others
Figure 14. Global Anti-VEGT Drugs Market Share by Type in 2022 & 2029
Figure 15. Global Anti-VEGT Drugs Sales in Value by Type (2018-2029) & (US$ Million)
Figure 16. Global Anti-VEGT Drugs Sales Market Share in Value by Type (2018-2029)
Figure 17. Global Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 18. Global Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 19. Global Anti-VEGT Drugs Price by Type (2018-2029) & (US$/Unit)
Figure 20. India Anti-VEGT Drugs Market Share by Type in 2022 & 2029
Figure 21. India Anti-VEGT Drugs Sales in Value by Type (2018-2029) & (US$ Million)
Figure 22. India Anti-VEGT Drugs Sales Market Share in Value by Type (2018-2029)
Figure 23. India Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 24. India Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 25. India Anti-VEGT Drugs Price by Type (2018-2029) & (US$/Unit)
Figure 26. Product Picture of Oncology
Figure 27. Product Picture of Ophthalmology
Figure 28. Product Picture of Others
Figure 29. Global Anti-VEGT Drugs Market Share by Application in 2022 & 2029
Figure 30. Global Anti-VEGT Drugs Sales in Value by Application (2018-2029) & (US$ Million)
Figure 31. Global Anti-VEGT Drugs Sales Market Share in Value by Application (2018-2029)
Figure 32. Global Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 33. Global Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 34. Global Anti-VEGT Drugs Price by Application (2018-2029) & (US$/Unit)
Figure 35. India Anti-VEGT Drugs Market Share by Application in 2022 & 2029
Figure 36. India Anti-VEGT Drugs Sales in Value by Application (2018-2029) & (US$ Million)
Figure 37. India Anti-VEGT Drugs Sales Market Share in Value by Application (2018-2029)
Figure 38. India Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 39. India Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 40. India Anti-VEGT Drugs Price by Application (2018-2029) & (US$/Unit)
Figure 41. Americas Anti-VEGT Drugs Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 42. Americas Anti-VEGT Drugs Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 43. Americas Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 44. Americas Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 45. Americas Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 46. Americas Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 47. United States Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 48. Canada Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 49. Mexico Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 50. Brazil Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 51. EMEA Anti-VEGT Drugs Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 52. EMEA Anti-VEGT Drugs Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 53. EMEA Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 54. EMEA Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 55. EMEA Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 56. EMEA Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 57. Europe Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 58. Middle East Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 59. Africa Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 60. China Anti-VEGT Drugs Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 61. China Anti-VEGT Drugs Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 62. China Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 63. China Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 64. China Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 65. China Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 66. APAC Anti-VEGT Drugs Sales in Volume Growth Rate 2018-2029 (K Units)
Figure 67. APAC Anti-VEGT Drugs Sales in Value Growth Rate 2018-2029 (US$ Million)
Figure 68. APAC Anti-VEGT Drugs Sales by Type (2018-2029) & (K Units)
Figure 69. APAC Anti-VEGT Drugs Sales Market Share in Volume by Type (2018-2029)
Figure 70. APAC Anti-VEGT Drugs Sales by Application (2018-2029) & (K Units)
Figure 71. APAC Anti-VEGT Drugs Sales Market Share in Volume by Application (2018-2029)
Figure 72. Japan Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 73. South Korea Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 74. China Taiwan Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 75. Southeast Asia Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 76. India Anti-VEGT Drugs Sales in Value Growth Rate (2018-2029) & (US$ Million)
Figure 77. Anti-VEGT Drugs Value Chain
Figure 78. Anti-VEGT Drugs Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed